Kornimate/medical-research-clean huggingface dataset:
tele-assessment of the performance tests in patients with knee osteoarthritis

Conditions: Telerehabilitation; Tele-assessment; Knee Arthritis Osteoarthritis; Performance Measures

Summary: the covid-19 pandemic widely affected delivery mode of healthcare services. while fewer number of patients were allowed to attend face-to-face rehabilitation sessions, some services were totally unavailable due to the safety measures. the covid-19 crisis highlighted the value and accelerated the improvement of "tele-assessment and tele-rehabilitation" applications. consequently, reliable remote assessment approaches were required to evaluate the effectiveness of the remote programs. while tests such as tug, sls, and 30cst are valid and reliable for clinical use in patients with knee oa, their psychometric properties are yet to be investigated when used as tele-assessment tests. therefore, this study aimed to examine the intra- and inter-rater reliability of the tug, sls, and 30cst as remote tests in patients with knee oa.

as the main cause of disability and loss of function in lower limb in middle-aged to elderly individuals , knee osteoarthritis (oa) is the most common oa worldwide and its prevalence increases with age and obesity . among non-pharmacological methods, which are the first line of knee oa treatment , physical therapy is commonly prescribed to alleviate pain and improve physical function. however, not all patients with knee oa have access to face-to-face rehabilitation sessions under direct supervision of physicians or physiotherapists. thanks to telemedicine, patients' access to real-time communication with health professionals has been considerably facilitated in recent years. detailed and comprehensive assessment is a fundamental factor for an effective rehabilitation program. different assessment tools are available to assess the effectiveness of rehabilitation in patients with knee oa. to assess physical performance, practical tests, which are time- and space-effective, such as timed up and go test (tug), thirty second chair stand test (30cst), and single leg stance test (sls) are commonly used in patients with knee oa .covid-19 crisis highlighted the value and accelerated the improvement of "tele-assessment and tele-rehabilitation" applications. consequently, reliable remote assessment approaches were required to evaluate the effectiveness of the remote programs.

Eligibility criteria:
inclusion criteria: * grade 2 and 3 knee oa on the kellgren and lawrence (k/l) scale, * radiologically confirmed * pain in the knee, * willingness to join the study exclusion criteria: * grade 0, 1 and 4 knee oa on the k/l scale, * central or peripheral nervous system involvement, * previous knee surgery within the past six months, * neurological or musculoskeletal disorders that would limit their performance on the tests, * history of systemic arthritic conditions

Keywords: knee osteoarthritis reliability single leg stance test tele-assessment thirty second chair stand test timed up and go test
short term pancreatic stenting registry

Conditions: Post-ERCP Acute Pancreatitis; Pancreatic Duct Stricture; Pancreatic Duct Stones; Pancreatic Duct Leakage

Summary: the purpose of this study is to document clinical utility and distribution of indications for short term pancreatic stenting, and stent type preference by indication at tertiary referral centers with expertise in pancreatic endotherapy.

the study is designed as an all-comer, prospective, multi-center, consecutive cohort series, open-label study. detailed objective: to confirm the clinical utility of advanix™ pancreatic stents when used per standard of practice to facilitate pancreatic duct drainage in the following clinical presentations: * group a: pep risk - in subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ercp) * group b: impaired pancreatic duct drainage - in subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after eswl or before pancreatic surgery * group c: pancreatic duct leak - in subjects with a pancreatic duct leak * group d: post pancreatic surgery - in subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy * group e: other - in subjects with other indications

Eligibility criteria:
inclusion criteria: 1. subjects age 18 or older. 2. subjects who require pancreatic drainage and are amenable to endoscopic techniques. 3. subjects willing and able to comply with the study procedures and follow up schedule and willing to provide written informed consent to participate in the study. 4. subjects satisfying at least one of the following clinical presentations: 1. high risk of acute pancreatitis post ercp 2. impaired pancreatic duct drainage and pain associated with a pancreatic duct dominant stricture and/or stones and/or sludge/debris, possibly before eswl or before pancreatic surgery 3. need to maintain proper pancreatic duct drainage in the presence of a pancreatic duct leak 4. need to maintain proper pancreatic duct drainage after surgical resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy exclusion criteria: 1. subjects for whom endoscopic techniques are contraindicated. 2. subjects with known sensitivity to any components of the stents or delivery systems. 3. subjects with coagulopathy outside of what is deemed acceptable for ercps per standard of practice 4. subjects who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor. 5. subjects unable or refusing to comply with the follow-up schedule including subject living at such a distance from the investigational center that attending follow-up visits would be unusually difficult or burdensome.
patterns of eye diseases among patients attending the eye investigation unit of sohag university hospital

Conditions: Eye Diseases

Summary: the goal of the work: is to assess the patterns of eye diseases in patients attending the eye investigation unit of sohag university hospital.organize the community education. the main question it aims to answer is * does eye disease blindness prevalence rate increase in women more than men? * what is the rate of glaucoma and other ocular diseases that causes irreversible blindness among the attending patients? patients attending to the eye investigation unit of sohag university hospital in the period from january 2025 to december 2025 are being observed in this work to determine the eye diseases prevalence.

this type of study is helpful to get an idea about the epidemiology of ocular disorders. it is necessary to organize the community education and ensure early treatment to reduce the prevalence of such diseases in the general population. * aim of the work: is to assess the patterns of eye diseases in patients attending the eye investigation unit of sohag university hospital. * study design: observational cross-sectional study.3 * patients and methods: all patients attending to the eye investigation unit of sohag university hospital in the period from january 2025 to december 2025. * inclusion criteria: all patients referred to the eye investigation unit from the outpatient clinic of sohag university hospital, private clinics or health insurance. * exclusion criteria: 1. patients unable to measure visual acuity. 2. patients unable to measure intraocular pressure. 3. mentally retarded patients. 4. undiagnosed patients. * time schedule: 1. twelve months for collection of data, writing the review of literature and methodology. 2. three months for analysis of data and writing the results. 3. three months for writing the discussion and conclusions. * ethical considerations: 1. the study adheres to tents of helsinki declaration. 2. the study will be approved by the ethical committee of the faculty of medicine sohag university. 3. an informed written consent will be taken from all of the participants in the study or their guardians

Eligibility criteria:
inclusion criteria: - all patients referred to the eye investigation unit from the outpatient clinic of sohag university hospital, private clinics or health insurance. exclusion criteria: * patients unable to measure visual acuity. * patients unable to measure intraocular pressure. * mentally retarded patients. * undiagnosed patients.

Keywords: patterns of eye disease
the sabre trial of hypertonic saline in acute bronchiolitis

Conditions: Acute Bronchiolitis

Summary: acute bronchiolitis is a common, distressing illness affecting children. a virus infects the lungs, and then the airways become blocked, leading to difficulties with breathing. it is the most common reason why children are admitted to hospital, with 1-3% of all children admitted to hospital during their first winter, creating enormous strains on nhs services. the majority of those admitted with the condition are under six months of age and the associated stress for parents is considerable. after forty years of research the best treatment we have is supportive care and oxygen. recent research suggests that salt water, sprayed as a mist so that the children can breathe it in ('nebulised 3% hypertonic saline') might help children with acute bronchiolitis. scientists think that the salt water changes the mucus which blocks the airways so that it can be cleared more easily. three small research studies all suggested that a child's time in hospital could be reduced by a quarter by using this treatment. if this was true, it would be good for children, their families and the children's wards trying to cope with the large numbers admitted with bronchiolitis every year. to decide whether this treatment should be used throughout the nhs, we need to run a randomised controlled trial of hypertonic saline in a large number of children. the trial will tell us if adding saline to usual care reduces distress in both children and parents, as well as whether it reduces the length of time they stay in hospital. we will then know if the treatment is the best thing for children with bronchiolitis and whether it provides the nhs with good value for money.


Eligibility criteria:
inclusion criteria: * previously healthy infants under 1 year of age * admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the uk definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation * requiring supplemental oxygen therapy on admission exclusion criteria: * wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations * previous lower respiratory tract infections * risk factors for severe disease \[gestation \<32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease\] * subjects where the carer's english is not fluent and translational services are not available * requiring admission to high dependency or intensive care units at the time of recruitment

Keywords: hospital admissions acute bronchiolitis under one year old requiring oxygen therapy
roflumilast in chronic obstructive pulmonary disease (copd) patients treated with fixed dose combinations of long-acting β2-agonist (laba) and inhaled corticosteroid (ics)

Conditions: COPD; COPD Exacerbation; Lung Diseases; Respiratory Disorders; Pulmonary Disease; Chronic Obstructive Lung Diseases; Chronic Obstructive Airway Disease

Summary: to demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (fdc) laba/ics in the reduction of exacerbations in subjects with severe to very severe copd.


Eligibility criteria:
inclusion criteria: * 1. male or female patients at least 40 years of age * 2. history of copd (according to global initiative for chronic obstructive lung disease \[gold\] 2010) for at least 12 months prior to screening (visit 1) associated with chronic productive cough for 3 months in each of 2 consecutive years (with other causes of productive cough excluded). only patients with chronic bronchitis will be included (concomitant emphysema is permitted) * 3. forced expiratory volume after 1 second (fev1)/forced vital capacity (fvc) ratio (postbronchodilator) \< 70% at screening (visit 1) * 4. fev1 (postbronchodilator) ≤ 50% of predicted at screening (visit 1) * 5. at least two documented moderate or severe copd exacerbations within 12 months prior to screening (visit 1) * 6. patients must be on fdc laba/ics treatment ≥ 3 months prior to screening (visit 1) * 7. former smokers (defined as smoking cessation at least 1 year ago) or current smokers (including patients who ceased smoking within the past year) both with a smoking history of at least 20 pack-years exclusion criteria: * 1. moderate or severe copd exacerbation and/or copd exacerbations treated with antibiotics or systemic glucocorticosteroids within 4 weeks of screening (visit 1) (ie, patients must be clinically stable) * 2. known alpha-1-antitrypsin deficiency * 3. current diagnosis of asthma (either controlled or uncontrolled) (note: history of childhood asthma is not exclusionary.) * 4. body mass index (bmi) ≥ 45 kg/m2 * 5. patients with a history (within 5 years) or current diagnosis of cancer other than basal or squamous cell skin cancer

Keywords: copd exacerbations roflumilast daliresp
sugammadex ed90 dose in the obese patients

Conditions: Incomplete Reversal of Neuromuscular Block

Summary: the purpose of this study is to determine the minimum effective dose of sugammadex, an antagonist of neuromuscular blockade used during anesthesia practice, in obese patients, considering that sugammadex is indicated in adults with normal weight at a dose of 2 mg/kg but no studies were found with obese patients.

prospective study with the sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ed90). the following doses were chosen: 2.0 mg.kg-1, 2.2 mg.kg-1, 2.4 mg.kg-1, 2.6 mg.kg-1, 2.8 mg.kg-1. the complete reversal of moderate rocuronium-induced neuromuscular blockade (nmb) considered a t4/t1 ratio ≥ 0.9 with the peripheral nerve stimulator and accelerometer (monitor of sequential electric stimuli) "train-of-four" (tof). after induction of general anesthesia and the calibration of the peripheral nerve stimulator and accelerometer, rocuronium 0.6 mg.kg-1 was injected. continuous intravenous infusion of the anesthetics propofol and remifentanil, and intermittent bolus of rocuronium were offered throughout the procedure.

Eligibility criteria:
inclusion criteria: * a body mass index ≥ 40 kg/m2 * bariatric surgery * informed consent signed exclusion criteria: * history of neuromuscular diseases, * use of drugs that could interfere with neuromuscular transmission, * allergy to neuromuscular agents of the aminosteroids class, * anticipated difficulty in airway management, * renal failure

Keywords: dose-response relationship drug obesity cyclodextrins
effect of rehabilitation on ejection fraction (fe) in cardiopathic and non cardiopathic patients undergoing major orthopedic surgery

Conditions: Cardiovascular Diseases

Summary: it is a trial aimed to evaluate the ejection fraction in the preoperative phase and during follow-up in two groups of subjects undergoing major orthopedic surgery: the first consisting of subjects without history of cardiac disease, and the second from subjects with a history of cardiopulmonary disease


Eligibility criteria:
inclusion criteria: * age: \ or equal 85 years * major orthopedic surgery * rehabilitation at our site * a positive history for the cardiopathic group exclusion criteria: * age: \> 85 and \< 18 * impossibility to participate to the rehabilitative protocol or come to the follow up visit * lack of consensus * previous acute cerebrovascular and / or cardiological events within 6 months prior to enrollment * previous myocardial (percutaneous and / or surgical) revascularization interventions within the 6 months prior to enrollment * previous (even in pediatric age) interventions of surgical correction of congenital heart disease * severe heart failure * reimplantation of prosthesis
grib forsoeget-2004

Conditions: Overweight

Summary: the difficulties in loosing weight may not stem from lack og knowledge about nutrition, as implied by the standard treatment but from difficulties in following the advice. the hypothesis is, that revealing and addressing these difficulties psychotherapeutically may be more efficient in obtaining weight reduction. the effect of psychological group treatment of severely overweight children and their parents is compared with traditional nutritional information. in other words: which is better: back-up or enlightenment?

at on-set the children get a medical examination, blood-tests, measurement of height, weight, skin-fold, waist and hip. children and parents fill out questionnaires on social and educational background as well as motivation and expectations to the treatment. all children are thereafter randomised into two groups:multi-disciplinary group intervention versus traditional information. the randomisation is stratified according to gender and degree of overweight (135%-145% and \>145%) supposing that the degree of overweight may mirror the difficulties in loosing weight. the experimental intervention consists of one lecture of general nutrition, weekly psychological group sessions for the children followed by physical exercise, and separate bi-monthly group sessions for the parents. after six months children and parents go to separate group sessions once a month for six months. the control group is offered nutritional advice once with a brief follow-up after one month. the height and weight of the children is measured every month, and the fat % is measured with dexa-scanning at on-set, after six months, and after twelve months

Eligibility criteria:
inclusion criteria: * weight compared to hight over 135% of the danish norms (www.peadiatri.dk) exclusion criteria: * none of the parents wants to participate * diagnosed somatic course of overweight * parents or children do not speak danish * sever physical handicap * psychiatric illness or mental retardation in children or parents * severe child abuse * siblings participation in the trail.

Keywords: obesity children psychological intervention
multiple oral dose safety, tolerability and pharmacokinetic study of pf-04287881 in healthy adult subjects

Conditions: Respiratory Tract Infections

Summary: this study is a randomized, investigator blind, subject blind, sponsor-open, placebo controlled, multiple dose escalating, sequential, parallel cohort study of pf-04287881. subjects will undergo screening procedures within 28 days prior to dosing. at least 1 day after the screening visit, eligible subjects who meet the entry criteria will be admitted to the clinical research unit (cru) and confined in the unit until discharge on day 15. approximately 60 healthy volunteers (20 volunteers of japanese origin for cohorts 5 and 6), 18 to 55 years of age, males and females (women of non childbearing potential only) will be enrolled and randomized in a 4:1 ratio to treatment with either pf-04287881 or placebo within each cohort. each cohort will have a 10 day dosing period and each will consist of 10 subjects (8 active and 2 placebo). in each cohort, each subject will receive a single daily oral dose of either placebo or pf-04287881 under fasted state for 10 days.

following a serious adverse event (potential hy's law case), a risk-benefit assessment review of all preliminary safety data, and a review by pfizer's internal hepatic injury advisory panel, it was concluded that pf-04287881 had an unacceptable therapeutic window. the fda was notified of our intention to discontinue development as of 09april2010.

Eligibility criteria:
inclusion criteria: * volunteers willing and able to be confined to the clinical research unit and comply with study schedule. * women of non-childbearing potential only. * japanese subjects must have 4 japanese grandparents who were born in japan. exclusion criteria: * previous antibiotic use within 14 days prior to dosing. * use of antibiotics during hospitalization within 90 days prior to dosing. * history of hypersensitivity to macrolides or ketolides. * presence of clinically significant eye conditions (other than corrective lenses).

Keywords: safety tolerability pharmacokinetics multiple-dose macrolide
initial safety evaluation of fibrofix™ meniscus

Conditions: Other Tear of Medial Meniscus, Current Injury

Summary: initial evaluation of safety and performance of fibrofix™ meniscus scaffold

the safety of the fibrofix™ meniscus scaffold will be evaluated in 10 patients scheduled for elective arthroscopic medial meniscus partial resection or treatment of asymptomatic medial meniscal defect

Eligibility criteria:
inclusion criteria: * the subject (or guardian, if appropriate) has signed and dated a specific informed consent form * the subject is over the age of 18 * the subject is able to comply with the protocol-defined preoperative procedures, the postoperative clinical and radiographic evaluations and the recommended rehabilitation regimen as determined by the investigator * the subject has a diagnosis of an mri or arthroscopically confirmed irreparable medial meniscus defect * the meniscal defect should represent 25% or more of the meniscus and be amenable to repair * the peripheral meniscal rim must be present * the subject has a functionally intact anterior cruciate ligament * haemoglobin \>9g/dl and platelet count \>100,000/mm3 prior to day 1 * no contraindication to general anaesthetic * female subjects of child-bearing potential: a negative urine pregnancy test exclusion criteria: * the subject has a functionally deficient anterior cruciate ligament * the subject has concomitant posterior cruciate ligament insufficiency of the involved knee or a concomitant injury that interferes with the subject's ability to comply with the recommended rehabilitation program * the subject has a diagnosis of untreatable grade iv outerbridge scale degenerative cartilage disease in the involved knee joint * patients demonstrating an active local or systemic infection * any condition, which in the judgment of the investigator would preclude adequate evaluation of the fibrofix™ meniscus scaffold and clinical outcome. * the subject has a history of confirmed anaphylactoid reaction * the subject has received local administration of any type of corticosteroid or systemic administration of antineoplastic, immunostimulating, or immunosuppressive agents within 180 days prior to the scheduled surgery * the subject has evidence of osteonecrosis of the involved knee * the subject has a medical history that includes a confirmed diagnosis of rheumatoid or inflammatory arthritis, or relapsing polychondritis * if female and of child-bearing potential: evidence of a positive pregnancy test or a stated intention to become pregnant in the next 6-12 months

Keywords: medial meniscus scaffold repair tear injury